H1 2022 revenue increased to ~$15.0 million, up 604% from H1 2021 and 117% from H2 2021, driven by House of BrandsGross Profit increased to ~$7.0 million, up 547% compared to H1 2021 and 363% compared to H2 2021Company reaffirms its 2022 revenue guidance to range between $35.0 million - $45.0 million, indicating approximately 300% - 400% projected revenue growth from 2021 In August, Flora…
Lexaria is a biotechnology company pursuing the enhancement of the bioavailability of a diverse and broad range of active pharmaceutical ingredients (“APIs”)The company has developed the patented DehydraTECH(TM) drug delivery technology, which has been shown to deliver more API at a faster rate than controlsLexaria’s DehydraTECH pipeline includes DehydraTECH-CBD for the treatment of hypertensionThrough pre-clinical studies, DehydraTECH-CBD has been shown to decrease systolic blood pressure…
Flora Growth is a global cannabis brand-builder focused on the cultivation of product at a central Colombian facility and marketing through a design-led international supply chainFlora recently announced an agreement with Colombia’s Misak tribe for cooperative processing and distribution of cannabis, drawing on the tribe’s licensing advantage to accelerate the pair’s marketing capacityFlora is headquartered in Canada, but its strength lies in its Colombian-based cultivation…
Lexaria’s development of its patented DehydraTECH(TM) technology since 2014 has yielded 27 patents in Australia, the United States, the European Union, Japan, India and Mexico with approximately 50 additional patents pending around the worldIts latest patent, granted in Mexico, applies a range of active ingredients, including but not limited to non-psychoactive cannabinoids and NSAIDs in a variety of ready-to-drink consumer retail beverage productsLexaria remains committed…
Lexaria Bioscience is a global innovator in drug delivery platforms whose lead technology, DehydraTECH, has been shown to increase the bioavailability of APIsThe company recently announced that Catherine Turkel, PharmD, Ph.D., has joined its board of directorsDr. Turkel, who brings over 20 years’ experience, has previously formulated Food and Drug Administration (“FDA”) registration and commercial strategic plans, as well as led global development programs for…
A 2017 study by McKinsey & Company showed that high performers tend to be 400% more productive than average ones. This outlook has shaped Flora Growth’s hiring strategy for 2022, with the appointment of several key individuals whose proven talents and productivity are seen as critical to the company’s goal of delivering the most compelling customer experiences, most recently with the appointment of Elshad Garayev as…
Lexaria’s Mexican patent “Stable Ready-to-Drink Beverage Compositions Comprising Lipophilic Active Ingredients” joins the ranks of previously issued patents in Australia, India, Japan and the EUThe patent allows the company to provide value in gaining regulatory approval for its DehydraTECH(TM)-enabled CBD for multiple indications in the health and wellness fieldAdditional claims to Mexican patent #390001 include Alzheimer’s disease, Parkinson’s disease, schizophrenia, Human Immunodeficiency Virus (“HIV”) dementia,…
Global cannabis brand-builder Flora Growth recently named a former Amazon financial executive as its new CFO Elshad Garayev will work with outgoing CFO Lee Leiderman to ensure a smooth transition of responsibility amid finalization of Flora’s mid-year financial filing with the SECFlora Growth is headquartered in Canada with cultivation operations centered in Colombia, where recent government administrations have opened regulatory processes for exporting cannabis derivatives for…
Lexaria, a global innovator of drug delivery platforms is looking to provide a FDA registered hypertension treatment with its patented DehydraTECH technologyThe company’s efforts are encapsulated in its DehydraTECH-CBD that has been shown to lower blood pressure as well as reduce arterial stiffnessAlthough hypertension is a devastating condition that can cause not only life-threatening illnesses but also death, only about 53% of Americans with the…
Lexaria’s latest broadcast highlights the company’s progress in finding a potential solution for hypertension treatment while also pointing out why such a solution is much needed at this pointSince the company began developing its patented DehydraTECH(TM) technology in 2014, it has made significant progress in its clinical studies, even as it currently focuses on human clinical research to evaluate the tolerability, safety, and efficacy of…
Lexaria is a global innovator of drug delivery platforms, including its patented DehydraTECH(TM) technologyThe company recently released information that would help its stakeholders research and understand how biotech and pharmaceutical companies are valuedBased on some of the methodologies used in valuation, Lexaria is positioned favorably as its DehydraTECH-processed CBD for the treatment of hypertension has successfully reached the IND application stage, with the program recently…
Lexaria’s successful HYPER-H21-2 human clinical study, whose results were announced in the first week of September 2021, laid the groundwork for the company’s patented DehydraTECH(TM)-processed CBD NDAChris Bunka, the company’s CEO, referred to the results as “statistically significant,” ultimately kickstarting the IND application process with the FDALexaria has since received a full written positive response from the FDA on its DehydraTECH-CBD, agreeing to the company’s…
Lexaria Bioscience, a global innovator in drug delivery platforms, recently announced partnerships with Premier Wellness Science Co., BevNology, AnodGen Bioceuticals, and Valcon Medical A/SAccording to coverage by Zacks Small-Cap Research, who value Lexaria at $15 per share, the most impactful of these partnerships is with Premier because the company is expected to start paying license fees in early SeptemberIn a June 7 Fireside Chat, Lexaria…
Lexaria just completed dosing for its HYPER H21-4 human clinical study that dosed 64 patients aged between 40 and 70 with measured elevated blood pressure, stage 1 and stage 2 hypertensionHYPER-H21-4, Lexaria’s most ambitious hypertension clinical study yet, builds on the success of HYPER-H21-1 and HYPER-H21-2, both completed in 2021It explores the use of the company’s patented DehydraTECH(TM) technology in the potential treatment of hypertensionLexaria…
Vertical farming projected to reach more than $25 billion by 2030, with a CAGR of 23.3%MRFR report notes that “vertical farming systems and technologies offer a superior approach to farming methods”ACTX GrowPods are essentially vertical micro-farms that can be placed anywhere, allow cultivation of a wide variety of crops, 365 days a year A recent Market Research Future (“MRFR”) report shows that vertical farming is…
In 2021, a staggering 45 million people were at emergency levels of acute hungerProviding access to food, sustainable food systems are key to WFP’s vision of eradicating food insecurity and malnutritionGrowPods create an optimum controlled environment for growing a wide range of crops in a variety of environments and climates With hunger on the rise again, companies and communities are working together to find realistic…
Lexaria, a global innovator in drug delivery technology, has developed the patented DehydraTECH(TM) technology which has been the subject of several issued patentsRecently, Lexaria reported it had been notified of the allowance of its 26th worldwide patent with a new patent to be granted in JapanThe patent is the fourth to be granted in Japan and the first patent issued from Lexaria’s seventh patent familyLexaria…
Researchers have run into the issue of solubility of molecules intended for absorption, ultimately affecting drug effectiveness and inhibiting patient recoveryThis has forced the exploration of new drug delivery technologies, with Lexaria’s patented DehydraTECH(TM) technology proving to be the most innovative, useful, and effectiveDehydraTECH(TM) technology has seen application in oral nicotine for reduced risk, antiviral drugs for COVID-19 and other infectious diseases, PDE5 inhibitors, and…
Lexaria's patented DehydraTECH(TM) enhancement technology targets key market segments including nicotine replacement, CBD, cardiovascular and antiviral drugs, human hormones, and PDE5 inhibitorsDehydraTECH-enabled drug and consumer products provide faster delivery times, increased bioavailability, increased brain absorption, improved drug potency, lower administration costs, and mask unwanted tastesThe global CBD market was valued at $5.18 billion in 2021 and is expected to grow at a CAGR of 16.8%…
Lexaria is a global innovator in drug delivery platformsThe company has developed the patented DehydraTECH(TM) technology that significantly improves the bioavailability of orally administered pharmaceuticals and therapeuticsBioavailability is the fraction of a drug that reaches the site of action or systemic circulationWhile drugs delivered intravenously are 100% bioavailable, drugs that have any other route of administration, such as oral, have reduced bioavailabilityDehydraTECH enhances the bioavailability…
Shareholders approve all proposals submitted at this year’s annual shareholders’ meeting, including board membersAmong the seven members of the Board of Directors elected, six were incumbents, making Brandon Konigsberg the newest addition to the BoardMr. Konigsberg will lend his years of experience, having held key leadership positions in various organizations in the countryLuis Merchan, Flora Growth’s Chairman and CEO, noted that Mr. Konigsberg’s appointment would…
Lexaria is a global innovator in drug delivery platforms; its patented DehydraTECH(TM) technology improves the bioavailability, speed of onset, and brain absorption of active pharmaceutical ingredients (“API”)Testing confirms that DehydraTECH-processed cannabidiol beverages maintained 93.4% and 78% potency of CBD a full year and two years after production, respectivelyLexaria recently signed two agreements with BevNology LLC, an Atlanta-based company with advanced capabilities that support best-in-class beverage…
Flora just announced the repurchase of $5 million of its outstanding common sharesThis repurchase aligns with its overall global expansion plan, and its move to grow its market reachThese moves by Flora assure shareholders of the company’s commitment to driving shareholder value and exploring various opportunities to do so On June 16, 2022, Flora Growth (NASDAQ: FLGC) announced that its Board of Directors had authorized…
Flora Growth is a cannabis cultivator and distributor with a base of operations in Colombia’s fertile growing climate, capable of feeding the company’s expanding international supply chainColombia has undergone a number of regulatory changes in recent years as it emerges from the shadows of years-long drug wars and embraces a growing global acceptance of cannabis productsThe South American country voted in a new presidential administration…
The two companies signed a manufacturing operating agreement and a commercial agreement Lexaria sent a pre-IND meeting request letter to the US FDA and plans to file the full IND application in late 2022/early 2023The FDA has acknowledged Lexaria's pre-IND request and responded with conditions prior to the target date of July 30, 2022 Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has…
Flora’s 2021 acquisitions allowed it to expand its operations beyond North America and into EuropeAcquisitions have also contributed to 450% YOY revenue growth for Q1 2022Its management is confident that the foundation laid down so far will yield growth for 2022 and subsequent financial yearsFlora has also reiterated 2022 revenue guidance of $35 million to $45 million 2021 was an excellent year for Flora Growth…
The global indoor farming market projected to grow from $26.5 billion in 2021 to $62 billion by 2030Report indicates that United States holds major share in terms of revenue in North America indoor farming marketGrow Pods offered through ACTX provide a controlled environment, ability to grow year-round The newest projections for the global indoor farming sector are in, and the numbers bode well for Advanced Container Technologies (OTC: ACTX). ACTX is…
Drug delivery technology innovator Lexaria Bioscience has developed a patented technology showing superiority in animal and human testing as a means of improving existing drug brands’ performance and establishing new solutions for unmet medical needsThe company recently announced agreements with beverage developer BevNology to expand production capabilities for Lexaria's own growing list of B2B clientele and empowering BevNology to offer DehydraTECH products with active ingredients…
Flora Growth Corp. announced that the Company Board has authorized the repurchase of up to $5 million of its outstanding common sharesLuis Merchan, Flora’s Chairman and CEO, said that Flora is executing its growth plans while simultaneously improving gross profit margins and reducing corporate overhead expensesAt the closing of 2021, the company announced a 2022 revenue guidance projection of $35-45 million Flora Growth (NASDAQ: FLGC)…
Tens of millions of adults, children are living in food-insecure householdsMicro-farms, such as ACTX’s Grow Pods, are being evaluated as a potential solution for food insecurityWith GrowPods, cultivation can be moved directly into the areas where food is needed An estimated 30 million adults and 12 million children are living in food-insecure households, reports a recent CNN Business article (https://ibn.fm/nnECx). Those are people that Advanced Container…
Lexaria sold Premier Wellness Science Co. exclusive rights to use its patented DehyraTECH(TM) in Japan in a variety of CBD productsValcon Medical A/S also signed an agreement with Lexaria to use its platform for medical cannabis applications in EuropeAnodGen Bioceuticals received a pharmaceutical license to use the platform for manufacturing and distributing CBD API powders in Europe, Australia, and New Zealand Lexaria Bioscience (NASDAQ: LEXX)…
Flora’s collaboration with Highsman seeks to elevate both Highsman and Vessel, Flora’s accessories brand, thereby inspiring greatness and creating an experience worth sharingThe company’s acquisition of Masaya allows it to deliver on its promise to invest in safe, thorough, and cutting-edge cannabis researchFlora’s product launch on Amazon.co.uk marks a big step in operations expansion in Europe The first half of 2022 has been successful for…
Drug bioavailability enhancement technology developer Lexaria Bioscience is working to increase the number of potential new solutions to unmet medical needs and improving existing treatments for other chronic conditionsLexaria’s patented DehydraTECH solution transforms a wide variety of orally and topically administered products into enhanced solutions that make the active pharmaceutical ingredients (“APIs”) more rapidly available and effective at lower doses DehydraTECH-enhanced products have also demonstrated the…
Flora Growth completed the acquisition of Just Brands LLC and High Roller Private Label LLC, owners of the JustCBD brand, on February 28, 2022The company then expanded its operational footprint in Europe and the UK in May 2022 to further its international growth strategyJustCBD products, including gummies and tinctures, will be available on www.Amazon.co.uk starting this month in a pilot-only programFlora Growth is optimistic that…
Lexaria, a global innovator of drug delivery platforms, recently filed a pre-IND meeting request letter with the FDA, initiating communication regarding the development of its DehydraTECH-CBD as a treatment for hypertensionThe company has been undertaking preparatory programs in readiness for the meeting, as well as an IND application filingThe pre-IND meeting will confirm the details of the company’s IND-enabling programLexaria also announced it had licensed…
The nicotine pouch market is projected to reach $21.84 billion in 2027, up from $2.33 billion in 2020, representing a CAGR of 30.7%The smokeless tobacco products sector is expected to post a CAGR of 7.2% over the forecast period (2018-2025)Lexaria, through its patented DehydraTECH technology, is tapping into this important alternative nicotine sector Its management is confident that its research and technology development investment will pay…
Flora Growth has appointed regulatory veteran Holly Bell as the new Vice President of Regulatory AffairsBell will help further the company’s domestic and global expansion strategy and lead government relations in key international marketsShe will also oversee the regulatory strategy supporting the advancement of the company’s cultivation, distribution, and pharmaceutical programsBell also participated in the first event in her new position- the Florida Industrial Hemp…
Lexaria Bioscience is a global innovator in drug delivery platforms, developing a technology designed to improve the performance of other medicinal products by making them more rapidly and effectively usable by patients’ bodiesLexaria’s patented DehydraTECH technology has been studied in combination with a number of other products, including but not limited to, cannabidiol (“CBD”), oral nicotine, antivirals, NSAIDs, and erectile dysfunction therapiesThe company is pursuing…
Prime Harvest is a California-based tech-driven full-service cannabis corporation focused on direct-to-consumer operations, licensing acquisition, compliance management, and state-wide deliveryPrime Harvest fuses integrity into operations, dedicated to redefining the customer experience, being a force for good within the communities they serve, while building a valuable enterpriseMember of Community Alliance Program (“CAP”), supports education, arts initiatives, and military veteran organizations in local Southern CaliforniaCompany launched Jaxx…
Lexaria is a biotechnology company focused on licensing its proprietary DehydraTECH(TM) technologyThe DehydraTECH technology has been proven to increase the bioavailability, speed of onset and brain absorption of APIs, and improve customer experiences by masking unwanted tastesLexaria has 25 patents granted worldwide and is pursuing numerous other pending patent applicationsThe company operates several subsidiary companies to focus on different commercial opportunities Ever since acquiring its…
To distribute a release in the next 24 hours. Contact our client services team.
Distribute a press release. Submit your release to get started.
Set up a Live demonstration. Schedule a date and time that works for you.
All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.
Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).